Source: International Congress 2015 – Notable abstracts in COPD: variety



Rating:

Share or cite this content

Citations should be made in the following way:
Demosthenes Bouros (Athens, Greece), Vassilios Tzilas, Evangelos Bouros, Danae Fourla, Athanasios Zisimopoulos, Nikolaos Papadopoulos, George Koliakos, George Kolios, Ioannis Pneumatikos, Vassilis Aidinis, Agyris Tzouvelekis, Demosthenes Bouros. Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE). Eur Respir J 2015; 46: Suppl. 59, 1970

Member's Comments

No comment yet.

Related content which might interest you: Preclinical studies of mesenchymal stem cell (MSC) transplantation in chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 A prospective, non randomized, clinical trial to study the safety and efficacy of the endobronchial autologous infusion of adipose-derived mesenchymal stem cells (ADMSCs) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Results immunophenotyping cultured autologous mesenchymal stromal cell of patients with COPD and IPF in Belarus Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer Source: Eur Respir J 2013; 41: 262-269 Year: 2013 Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013